Mapping of health technology assessment in China: a comparative study between 2016 and 2021

Shimeng Liu,Yu Xia,Yi Yang,Jian Ming,Hui Sun,Yan Wei,Yingyao Chen

DOI: https://doi.org/10.1186/s41256-023-00339-6

2024-01-16

Global Health Research and Policy

Abstract:Abstract Background Health Technology Assessment (HTA) in China has recently expanded from purely academic research to include policy or decision-oriented practice, especially after HTA evidence was used to update the National Reimbursement Drug List for the first time in 2017. This study aims to identify the progress and challenges of HTA development from 2016 to 2021 and inform policies and decisions to promote further HTA development in China. Methods We conducted a cross-sectional web-based survey with policy makers, researchers and industry-providers in China in 2016 and 2021 respectively. The ‘Mapping of HTA Instrument’, was utilized to assess the HTA development across eight domains: Institutionalization, Identification, Priority setting, Assessment, Appraisal, Reporting, Dissemination of findings and conclusions, and Implementation in policy and practice. To reduce the influence of confounders and compare the mapping outcomes between the 2016 and 2021 groups, we conducted 1:1 Propensity Score Matching (PSM). Univariate analysis was conducted to compare the differences between the two groups. The overall results were further compared with those of a mapping study that included ten countries. Results In total, 212 and 255 respondents completed the survey in 2016 and 2021, respectively. The total score of the HTA development level in China in 2021 was higher than that in 2016 before PSM (89.38 versus 83.96). Following PSM, 183 respondents from the 2016 and 2021 groups were matched. Overall, the mean scores for most indicators in the Institutionalization domain and Dissemination domain in 2021 were higher than those in 2016 ( P < 0.05). The Appraisal domain in 2021 was more explicit, transparent and replicable than that in 2016 ( t = −3.279, P < 0.05). However, the mean scores of most indicators in the Assessment domain were higher in 2016 than those in 2021 ( P < 0.05). Conclusions Our study suggest that the level of HTA development in China progressed significantly from 2016 to 2021. However, before engaging in HTA activities, further efforts are required to enhance the assessment process. For instance, it is important to establish a clear goal and scope for HTA; adapt standardized methodologies for evaluating the performance of systematic reviews or meta-analyses; and provide comprehensive descriptions of the safety, clinical effectiveness, cost, and cost-effectiveness of the assessed technologies, thus improving the development of HTA in China.

public, environmental & occupational health

What problem does this paper attempt to address?

The paper primarily explores the development level and challenges of Health Technology Assessment (HTA) in China from 2016 to 2021. The study collected views from policymakers, researchers, and industry providers through a cross-sectional online survey and used the "HTA Mapping Tool" to evaluate eight domains:

1. **Institutionalization**: Evaluates the interest and support of the government and policymakers for HTA, and whether China has formal HTA institutions.

2. **Identification**: Examines whether there is a monitoring system to identify technologies that need to be assessed.

3. **Priority setting**: Assesses the transparency and goal alignment of the priority-setting process.

4. **Assessment**: Evaluates the clarity of objectives and scope, the description of alternative technologies, the comprehensiveness of assessment content, the application of standardized methods, and the generalizability and transferability of HTA programs.

5. **Appraisal**: Assesses the clarity, transparency, and reproducibility of the appraisal process.

6. **Reporting**: Evaluates the use of reporting guidelines and the number of reports.

7. **Dissemination of findings and conclusions**: Assesses the timeliness of report dissemination and the effectiveness of dissemination strategies.

8. **Implementation in policy and practice**: Evaluates the mechanisms for providing information and measuring the impact of HTA in policy and practice.

The study results indicate that the overall development level of HTA in China in 2021 was higher than in 2016, with significant improvements in the domains of institutionalization and dissemination. However, the score in the assessment domain was relatively low in 2021, indicating that further efforts are needed in the assessment process. For example, it is necessary to clarify the objectives and scope of HTA, adopt standardized methods to evaluate the performance of systematic reviews or meta-analyses, and provide comprehensive descriptions of the safety, clinical effectiveness, cost, and cost-effectiveness of the assessed technologies to improve the development of HTA in China.

Overall, although China has made some progress in HTA, it still faces several challenges, particularly in institutionalization and the assessment process. To promote the continuous development of HTA in China, it is necessary to strengthen the construction of national-level HTA institutions, improve the quality of assessments, and establish more mature mechanisms for applying HTA evidence in decision-making in the future.